BiologyWorks k(now)™ COVID-19 Clinical Trial Matches 99.1% Accuracy to RT-PCR Tests
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LOS ANGELES -- Businesswire -- BiologyWorks™, Inc., a digital healthcare platform company, today announced that a substantive clinical trial of its handheld, reusable molecular test for COVID-19 matched 99.1% accuracy to laboratory RT-PCR tests.
The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19. For the study, staff at the clinical laboratory collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the lab’s standard of care CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k(now). Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests.
In addition to the clinical trial conducted by Locus Medicus, other independent validation studies of BiologyWorks k(now) have been conducted by the University of California, Los Angeles (UCLA), the Los Angeles Department of Public Health/Housing Services and Streeklab in Haarlem, Netherlands. Moreover, the Company verified the efficacy of BiologyWorks k(now) with over 12,000 tests in its Southern California lab. These studies also validate that the BiologyWorks k(now) molecular COVID-19 test provides RT-PCR lab quality results.
“Our Company’s priority is to make lab-quality testing accessible, accurate and affordable for everyone,” said Hunt Ramsbottom, CEO of BiologyWorks. “These clinical trials confirm that our handheld, reusable test is among the most accurate for COVID-19.” Hunt continued, “We give individuals and providers a highly reliable testing platform, with significantly lower cost per result and shortened time to results.”
BiologyWorks’ molecular test works in conjunction with the k(now) PRO™ digital platform, which provides point-of-care (POC) providers with a complete solution for end-to-end testing management. POC providers and patients simultaneously receive verified results within 45 minutes, giving individuals control of their health data. The BiologyWorks k(now) PRO digital platform complies with the most rigorous privacy standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the EU General Data Protection Regulation (GDPR).
About BiologyWorks
BiologyWorks™ (www.biologyworks.com) is the creator of BiologyWorks k(now)™ molecular test and the k(now) PRO™ digital platform. Together, these products offer point-of-care providers with a complete solution for highly accurate and affordable end-to-end testing management. The Company’s chemistry is patent-protected, based on research originating with the Alfred Mann Foundation, and is underwritten by a grant from the Bill & Melinda Gates Foundation.
For sales inquiries, please contact: sales@biologyworks.com
Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52563612/en
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:BiologyWorks, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 무료 관람 무용 축제, 앰비규어스댄스컴퍼니 ‘2024 페스티벌 99.9’ 6월 한강 세빛섬 야외무대서
- 삼성스토어, 전기차 충전소 매장 확대…고객 편의 강화 - 뉴스와이어
- LG화학, 국내 민간기업 최대 규모 풍력발전 재생에너지 확보 - 뉴스와이어
- 대한항공, 에어라인 레이팅스 ‘올해 최고 항공사 중 2위’ - 뉴스와이어
- 이찬원, 마이원픽 내 KM차트 5월 선호도 조사 참여도 전체 1위 달성 - 뉴스와이어
- 한화그룹 ‘타임 세계 영향력 있는 100대 기업’ 선정 - 뉴스와이어
- 상상이 현실이 되는 바다 ‘제14회 화성 뱃놀이 축제’ 개막 - 뉴스와이어
- ‘2024 박물관·미술관 주간’ 행사 성료 - 뉴스와이어
- 아모레퍼시픽, 중국·북미·일본 법인장 인사 - 뉴스와이어
- 닛폰 산소 홀딩스, 호주 자회사가 호주 북부·서부의 LPG 사업 인수 - 뉴스와이어